Drug Pipeline

Methotrexate Clinical Trials

Data updated daily from ClinicalTrials.gov — last refresh 2026-06-12
266
Active Studies
119
Recruiting
46
Phase 3
10
Top Sponsors
52
Changes, 30 Days
What Changed in the Last 30 Days
DetectedTrialChange
2026-06-11 NCT07388498
A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and…
Trial sites expanded: 37 -> 49 locations
2026-06-11 NCT07388498
A Double-blind, Randomized Controlled Trial to Investigate the Efficacy, Safety, and…
date change Completion moved earlier: 2028-07-18 -> 2028-06-18
2026-06-11 NCT07015242
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line…
Trial sites reduced: 82 -> 40 locations
2026-06-10 NCT05254743
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic…
Enrollment increased: 662 -> 737 participants
2026-06-10 NCT05254743
A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic…
date change Primary completion pushed: 2025-06-10 -> 2027-10
2026-06-06 NCT01804686
A Long-term Extension Study of PCI-32765 (Ibrutinib)
date change Completion pushed: 2027-08-31 -> 2029-12-31
2026-06-06 NCT05639647
Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for…
date change Primary completion pushed: 2026-08-17 -> 2027-03-31
2026-06-06 NCT05639647
Study of 2 Medicines (Aztreonam and Avibactam) Compared to Best Available Therapy for…
date change Completion pushed: 2026-08-17 -> 2027-03-31
2026-06-06 NCT07412470
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults…
Trial sites expanded: 16 -> 23 locations
2026-06-05 NCT06872333
Allo HSCT for High Risk Hemoglobinopathies
Trial arms changed: 4 -> 5
2026-06-05 NCT06536049
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell…
date change Primary completion pushed: 2026-12-31 -> 2027-08-31
2026-06-05 NCT06536049
Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell…
date change Completion moved earlier: 2028-12-31 -> 2027-10-31
2026-06-05 NCT03960840
Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL
date change Completion pushed: 2027-06-30 -> 2028-05-31
2026-06-03 NCT05663866
Premedication to Reduce Amivantamab Associated Infusion Related Reactions
date change Completion pushed: 2026-07-30 -> 2027-03-31
2026-06-02 NCT04739813
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With…
overall status: "Recruiting" → "Active Not Recruiting"
2026-06-02 NCT04739813
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With…
Enrollment reduced: 55 -> 34 participants
2026-06-02 NCT04739813
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With…
date change Primary completion moved earlier: 2026-06-18 -> 2026-05-07
2026-06-02 NCT04628767
Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients…
Enrollment reduced: 249 -> 131 participants
2026-05-30 NCT07280156
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused…
Trial sites expanded: 18 -> 27 locations
2026-05-29 NCT07280156
A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused…
Trial sites expanded: 1 -> 18 locations
Showing 20 of 52 changes detected in the last 30 days.
New Trial Filings, Last 30 Days
First PostedTrialPhaseStatus
2026-06-11 NCT07643038 Treatment Strategy for Patients With RA-ILD Phase 4 Not Yet Recruiting
2026-06-11 NCT07643103 Immuno-Targeted Therapy Plus Low-Dose Chemotherapy for Newly Diagnosed Adult Ph-Negative… Phase 2 Not Yet Recruiting
2026-06-09 NCT07634536 Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell… Phase 2 Not Yet Recruiting
2026-06-09 NCT07636564 Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute… Phase 2 Not Yet Recruiting
2026-06-04 NCT07627893 Complementary Herbal Approach to Rheumatoid Management Study (CHARMS) Phase 2/3 Not Yet Recruiting
2026-06-03 NCT07623200 A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With… Phase 3 Not Yet Recruiting
2026-06-03 NCT07624903 Letrozole Versus Methotrexate for Management of Undisturbed Ectopic Pregnancy Phase 2 Not Yet Recruiting
2026-06-02 NCT07619898 PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in… Phase 2 Not Yet Recruiting
2026-05-26 NCT07605364 Testing the Addition of an Anti-Cancer Drug, Mycophenolate Mofetil, to the Usual… Phase 2/3 Not Yet Recruiting
2026-05-22 NCT07603440 Intravenous Thrombolysis With Tenecteplase Plus Thrombectomy Versus Thrombectomy Alone In… Phase 3 Not Yet Recruiting
Active Studies by Phase
Phase 4
14
Phase 3
39
Phase 2/3
7
Phase 2
133
Phase 1/2
18
Phase 1
45
Early Phase 1
4
Not specified
6
Active Trials — top 25 of 266
NCT IDTitleConditionStatus
Phase 4
NCT07381556 Cyclosporine Or Methotrexate for Pediatric Alopecia Areata: Routine Clinical Care… Alopecia Areata(AA) Recruiting
NCT07486843 Preventing Structural Damage in Early Psoriatic Arthritis Psoriatic Arthritis (PsA) Recruiting
NCT06289673 Identification of Necessary Information for Treatment Induction in Newly Diagnosed Acute… Acute Lymphoblastic Leukemia Recruiting
NCT07432815 Treatment of Psoriasis With Depression and/or Anxiety With Methotrexate vs Combined… Depression Recruiting
NCT04877522 Asciminib Roll-over Study Chronic Myelogenous Leukemia Recruiting
NCT02081755 Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer Carcinoma, Hepatocellular Enrolling by Invitation
NCT07406204 Tofacitinib vs Methotrexate for Severe Alopecia Areata (TOFA-MTX-AA) Alopecia Areata Not Yet Recruiting
NCT05193565 Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in… Kidney Transplantation Active, Not Recruiting
NCT07477691 Immune Modulation During Palynziq® Treatment in Adults (IMPALA) Phenylketonuria Not Yet Recruiting
NCT06578728 Local Methotrexate Injections for the Treatment of Nail Psoriasis Nail Psoriasis Active, Not Recruiting
NCT07570433 HORUS-Cytomegalovirus Open Proof-of-concept Exploratory Trial CMV Infection Not Yet Recruiting
NCT07432386 Methotrexate Versus Apremilast for Pruritus in Psoriasis Psoriasis Not Yet Recruiting
NCT07352566 Utilization of a Microdevice for Psoriasis and Atopic Dermatitis Psoriasis Not Yet Recruiting
NCT07643038 Treatment Strategy for Patients With RA-ILD Rheumatoid Arthritis Associated Interstitial Lung Disease Not Yet Recruiting
Phase 3
NCT04877288 A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney… Renal Allograft Recipients Recruiting
NCT07377578 A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With… Mantle Cell Lymphoma Recruiting
NCT03593759 Cardiac Sarcoidosis Randomized Trial Cardiac Sarcoidosis Recruiting
NCT03959085 Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk… B Acute Lymphoblastic Leukemia Recruiting
NCT04293562 A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for… Acute Myeloid Leukemia Recruiting
NCT04307576 A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Leukemia, Acute Lymphoblastic Recruiting
NCT04043494 International Cooperative Treatment Protocol for Children and Adolescents With… Lymphoblastic Lymphoma, Childhood Recruiting
NCT06615050 A Study of Tacrolimus/Methotrexate/Ruxolitinib Versus Post-Transplant… Graft-versus-host Disease (GVHD) Recruiting
NCT06136559 A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib… Chronic Lymphocytic Leukemia Recruiting
NCT03150693 Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly… B Acute Lymphoblastic Leukemia Recruiting
NCT01804686 A Long-term Extension Study of PCI-32765 (Ibrutinib) Chronic Lymphocytic Leukemia Recruiting
Sponsors Running Methotrexate Trials
Disease Areas
Get alerts when Methotrexate trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free